Gold nanorods mediated controlled release of doxorubicin: Nano-needles for efficient drug delivery

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 7, 2013, Pages 1671-1681

  Pandey, Sunil ^a   Shah, Ritu ^a   Mewada, Ashmi ^a   Thakur, Mukeshchand ^a   Oza, Goldie ^a   Sharon, Madhuri ^a  

^a N S N Research Centre for Nanotechnology and Bionanotechnology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; CONTROLLED RELEASE; DOXORUBICIN; DRUG LOADING CAPACITY; EFFICIENT DRUG DELIVERY; GOLD NANOROD; GOLD NANORODS (GNRS); PHYSIOLOGICAL CONDITION;

DRUG DELIVERY; GOLD; NANORIBBONS; NANORODS; PLASMONS;

LOADING;

DOXORUBICIN; FOLIC ACID; GOLD NANOPARTICLE; GOLD NANOROD; MERCAPTAMINE; NANOCARRIER; NANOROD; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; IN VITRO STUDY; KINETICS; NANOFABRICATION; PH; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EFFICIENCY; GOLD; HUMANS; MATERIALS TESTING; NANOTECHNOLOGY; NANOTUBES; NEEDLES; NEOPLASMS;

EID: 84879797729     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-4915-4     Document Type: Article

References (43)

1. Kataoka K, Kwon G, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1992;24:119-32.
2. Kwon GS, Okano T. Polymeric micelle as new drug carriers. Adv Drug Deliv Rev. 1996;16:107-16.
3. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugates for sustained release. Pharm Res. 1999;16:1114-8.
4. Minko T, Kopeckova P, Pozharov V, Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release. 1998;54:223-33.
5. Verdiere C, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug resistant leukemic murine cells. Cancer Chemother Pharmacol. 1994;33:504-8.
6. Song C, Lyon JC, Luo Y. Intra and extracellular pH in solid tumors: influence on therapeutic response. In: Teicher BV, editor. Drug resistance in oncology. New York: Marcel Dekker; 1993. p. 25-51.
7. Song CW, Park HJ, Ross BD. Intra and extracellular pH in solid tumors. In: Teicher BV, editor. Antiangiogenic adnets in cancer therapy. Totowa: Humana; 1998. p. 51-64.
8. Webb SD, Sherratt JA, Fish RG. Mathematical modeling of tumour acidity: regulation of intracellular pH. J Theor Biol. 1999;196:237-50.
9. Gilles RJ, Raghunand N, Karczmar GS. MRI of the tumor microenvironment. J Magn Reson Imaging. 1999;16:430-50.
10. Svastove E, Hulikova A, Rafajova M. Hypoxia activates the capacity of tumor associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2000;19:35-439.
11. Aisenberg AC. The glycolysis and respiration of tumors. Nature. 1961;261:702-5. New York: Academic Press.
12. Kim GE, Lyons JC, Levitt SH, Song CW. Effects of amiloride on intracellular pH and thermosensitivity. Int J Radiat Oncol Biol Phys. 1991;20:541-9.
13. Gabizon, Horowitz AT, Goren D, Tzemach D, Man-delbaum-Shavit F, Qazen MM, Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethyleneglycol)-grafted liposomes: in vitro studies. Bioconjug Chem. 1999;10:289-98.
14. Guo W, Lee T, Sudimack JJ, Lee RJ. Receptor-specific delivery of liposomes via folate-PEG-chol. J Liposome Res. 2000;10:179-95.
15. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother. 2002;51:153-62.
16. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233:134-44.
17. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumors which exhibit different responses to the drug. Br J Cancer. 1986;53:835-8.
18. Pandey S, Oza G, Kesarkar R, Gupta A, Vishwanathan M, Shah R, Sharon M, Sharon M. Taguchi optimization method for tuning aspect ratios for synthesis of gold nano rods. Arch Appl Sci Res. 2012;4(2):965-70.
19. Oza G, Pandey S, Shah R, Vishwanathan M, Kesarkar R, Sharon M, Sharon M. Tailoring aspect ratio of gold nano rods: impact of temperature, pH, silver ions, CTAB concentration and centrifugation. Adv Appl Sci Res. 2012;3(2):1027-38.
20. Dubin CH. Special delivery: pharmaceutical companies aim to target their drugs with nano precision. Mech Eng Nanotechnol. 2004;126:10-2.
21. Dass CR, Su T. Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from genotherapy. Drug Deliv. 2001;8:191-213.
22. Pandey S, Oza G, Mewada A, Shah R, Thakur M, Sharon M. Folic acid mediated synaphic delivery of doxorubicin using biogenic gold nanoparticles anchored to biological linkers. J Mater Chem B. 2013;1:1361-70.
23. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002;19:425-98.
24. Senior K. Nano-dumpling with drug delivery potential. Mol Med Today. 1998;4:321.
25. DA LV, Lynn DM, Langer R. Moving smaller in drug discovery and delivery. Nat Rev Drug Discov. 2002;1:77-84.
26. DA LV, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21:1184-91.
27. Xiao Y, Hong H, Matson VZ, Javadi A, Xu W, Yang Y, Zhang Y, Engle JW, Nickles RJ, Cai W, Steeber DA, Gong S. GNRs conjugated with doxorubicin and cRGD for combined anti-cancer drug delivery and PET imaging. Theranostics. 2012;8:757-68.
28. Ravi KMN. Nano and microparticles as controlled drug delivery devices. J Pharm Sci. 2000;3:234-58.
29. Costa P, Sousa LJM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.
30. Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001;48:229-47.
31. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
32. Gallagher KM, Corrigan OI. Mechanistic aspects of the release of levamisole hydrochloride from biodegradable polymers. J Control Release. 2000;69:261-72.
33. Barua, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA. 2013;. doi: 10.1073/pnas.121689311.
34. Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology catalysis, and nanotechnology. Chem Rev. 2004;104:293-346.
35. Sharma V, Park K, Srinivasarao M. Colloidal dispersion of GNRs: historical background, optical properties, seed-mediated synthesis, shape separation and self-assembly. Mater Sci Eng R. 2009;65:1-38.
36. Link S, El-Sayed M. A size, temperature dependence of the plasmon absorption of colloidal gold nanoparticles. J Phys Chem B. 1999;103:4212-7.
37. Gans R. On the shape of ultramicroscopic gold particles. Annalen Der Physik. 1912;37:881-900.
38. Templeton AC, Hostelter MJ, Kraft CT, Murray RW. Reactivity of monolayer-protected gold cluster molecules: steric effects. J Am Chem Soc. 1998;120:1906-11.
39. Johnson SR, Evans SD, Mahon SW, Ulman A. Alkanethiol molecules containing an aromatic moiety self-assembled onto gold clusters. Langmuir. 1997;13:51-7.
40. Colin BD, Evall J, Whitesides GM. Formation of monolayers by the coadsorption of thiols on gold: variation in the head group, tail group, and solvent. J Am Chem Soc. 1989;111:7155-64.
41. Bhattacharya R, Patra CR, Earl A, Wang S, Katarya A, Lu L, Kizhakkedathu JN, Yaszemski MJ, Greipp PR, Mukhopadhya D, Mukherjee P. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomedicine. 2007;3:224-38.
42. Aryal S, Grailer JJ, Pilla S, Steeberb DA, Gong. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. J Mater Chem. 2009;19:7879-84.
43. Ulbrich K, Subr V. Polymeric anti cancer drugs with pH controlled activation. Adv Drug Deliv Rev. 2004;56:1023-50.